Show simple item record

dc.contributor.authorPadmanabhan, N
dc.contributor.authorHowell, Anthony
dc.contributor.authorRubens, R D
dc.date.accessioned2010-11-09T15:19:31Z
dc.date.available2010-11-09T15:19:31Z
dc.date.issued1986-08-23
dc.identifier.citationMechanism of action of adjuvant chemotherapy in early breast cancer. 1986, 2 (8504):411-4 Lanceten
dc.identifier.issn0140-6736
dc.identifier.pmid2874411
dc.identifier.doi10.1016/S0140-6736(86)92131-8
dc.identifier.urihttp://hdl.handle.net/10541/115166
dc.description.abstractThe relation between tumour oestrogen and progesterone receptor status, menstrual status, relapse-free survival, and overall survival was analysed in 411 patients with early breast cancer randomised to receive either postoperative adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF) or no additional treatment (control). Prolongation of time to recurrence and survival was seen predominantly in premenopausal patients; these effects were seen only with tumours positive for steroid receptors, particularly progesterone. Chemotherapy led to permanent amenorrhoea in 61% of premenopausal patients. The therapeutic effects of chemotherapy were seen only when CMF induced permanent amenorrhoea in premenopausal patients. These findings support the hypothesis that the effect of adjuvant chemotherapy in early breast cancer may be mediated by ovarian suppression.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectOestrogen Receptorsen
dc.subject.meshAdult
dc.subject.meshAge Factors
dc.subject.meshAged
dc.subject.meshAmenorrhea
dc.subject.meshBreast Neoplasms
dc.subject.meshClinical Trials as Topic
dc.subject.meshCombined Modality Therapy
dc.subject.meshCyclophosphamide
dc.subject.meshFemale
dc.subject.meshFluorouracil
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshMastectomy
dc.subject.meshMenopause
dc.subject.meshMethotrexate
dc.subject.meshMiddle Aged
dc.subject.meshPostoperative Period
dc.subject.meshRandom Allocation
dc.subject.meshReceptors, Estrogen
dc.subject.meshReceptors, Progesterone
dc.subject.meshTime Factors
dc.titleMechanism of action of adjuvant chemotherapy in early breast cancer.en
dc.typeArticleen
dc.identifier.eissn1474-547X
dc.contributor.departmentImperial Cancer Research Fund Clinical Oncology Unit, Guy's Hospital, London SE1, United Kingdomen
dc.identifier.journalLanceten
html.description.abstractThe relation between tumour oestrogen and progesterone receptor status, menstrual status, relapse-free survival, and overall survival was analysed in 411 patients with early breast cancer randomised to receive either postoperative adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF) or no additional treatment (control). Prolongation of time to recurrence and survival was seen predominantly in premenopausal patients; these effects were seen only with tumours positive for steroid receptors, particularly progesterone. Chemotherapy led to permanent amenorrhoea in 61% of premenopausal patients. The therapeutic effects of chemotherapy were seen only when CMF induced permanent amenorrhoea in premenopausal patients. These findings support the hypothesis that the effect of adjuvant chemotherapy in early breast cancer may be mediated by ovarian suppression.


Files in this item

This item appears in the following Collection(s)

Show simple item record